Lieberman on Psychiatry

 
 

  • Would President Trump Pass the Air Force's Nuclear Evaluation?   Dr Lieberman suggests that candidates for President should pass a psychological evaluation similar to the Air Force's PRP to determine their mental health.
  • The Dangers of Speculating About Trump's Mental Health   A book offering clinical assessments of President Trump's mental health has become a best seller. It's also a threat to psychiatry's reputation, says Dr Jeffrey Lieberman.
  • Misplaced Ecstasy? Questioning the Role of Psychedelics as Therapy   Dr Jeffrey Lieberman scrutinizes the current trend of repurposing 'feel good' drugs for serious mental conditions.
  • One Doctor's Ketamine Concern   After receiving a solicitation from a ketamine clinic, Dr Jeffrey Lieberman did some digging. What he found troubled him.
  • Revolutionizing Mental Health Care Through Technology   Dr Lieberman urges the private sector and academia to move ahead with smartphone and mobile device technologies.
  • One Step Forward, Two Steps Back: The US Healthcare Struggle   US healthcare policy is a Gordian knot, says Dr Lieberman, and current congressional machinations will not solve it.
  • Politics Are Sick. Time to Call a Doctor?   By infusing government with scientists and clinicians, we might get a healthier democracy, Dr Jeffrey Lieberman argues.
  • Two Major Developments in Psychiatry   Dr Jeffrey Lieberman discusses the process of updating the DSM on an ongoing basis, along with a rigorous new study on antipsychotic therapies.
  • What Should the Public Know About a President's Mental Health? Dr Jeffrey Lieberman argues that it's time we devised a system of vetting the physical and mental health of presidential candidates.
  • 'I'm Mad as Hell!': Healthcare in America Today   Dr Lieberman offers perspective on the healthcare landscape in America, repeal of the Affordable Care Act, and fiscal implications associated with clinical research and NIH funding.
  • Mental Health Docs Must Resist Armchair Diagnoses of Trump   According to Dr Jeffrey Lieberman, history shows a slippery slope away from ethics when psychiatrists, psychologists, and analysts play politics.
  • An Extraordinary Legislative Gain for Mental Health Care   The 21st Century Cures Act is broad in scope and potential impact on mental health care and research--and 'a marvelous synergy of good legislation,' declares Dr Lieberman.
  • Our Short-Sighted Mental Health Policies   Dr Lieberman laments our self-defeating inaction on mental health care and challenges all of us to redouble our efforts and press for change.
  • It's Morning in America for Mental Health Care   For the first time in recent memory, a presidential candidate has elevated mental health care to the level of a major priority, says Dr Lieberman.
  • Mental Health and the Presidency Dr Jeffrey Lieberman discusses the personality traits he feels drive people to seek political office.
  • Historic Day or a Missed Opportunity in Mental Health Care?   HR 2646 could be a mental health care game changer, but only if its many consequential elements are retained by the Senate, says Dr Lieberman.
  • Improving Drug Trials: Lessons Learned From Aripiprazole   Dr Lieberman discusses the FDA's recent warning about the side effects of aripiprazole, what we can learn from this, and how we can better manage a new drug's uncertain potential in the future.
  • While Rome Burns: Addressing Rising Suicide Rates   In the wake of rising suicide rates, Dr Lieberman urges us not to follow Nero's lead but to act to change the trajectory of these shocking statistics.
  • Genetics and Psychiatry: Let's Proceed With Caution   Dr Lieberman discusses three publications that illustrate the increasing role of genomics in psychiatry, cautioning against getting too excited too soon.
  • Two Bright Lights on the Healthcare Horizon   Dr Lieberman describes new healthcare legislation that can reverse the erosion of healthcare research/development of the past decade and improve your healthcare practice.
  • Psychedelic Drugs Redux: Don't Leapfrog the Research   Research trials of psychedelic drugs were truncated by the politics of the 1960s. Dr Lieberman explains why we need to begin studying them again, before public opinion gets ahead of what we know.
  • Should Celebrities Speak Out About Illness?   What is the fallout from celebrities championing causes in health and illness? Dr Jeffrey A. Lieberman discusses negatives and positives.
  • Second Chance for Mental Health Crisis Act   Congressman Tim Murphy takes another stab at pushing this landmark legislation across the finish line. Dr Lieberman explains how important these long-overdue reforms are for everyone.
  • What Does the New York Times Have Against Psychiatry?   Dr Jeffrey Lieberman's not-so-pleased reaction to a recent New York Times article on mental illness.
  • Ketamine in Psychiatry: Take Care   Dr Lieberman discusses the experience with ketamine and its promise for patients with refractory psychiatric conditions but cautions that it be used carefully and in a professional and rigorous way.
  • Understanding the Brain   Dr Jeffrey Lieberman discusses our ongoing attempt to understand the brain and thereby improve psychiatric care.
  • Robin Williams' Suicide Had Nothing to Do With Demons   In the wake of actor Robin Williams' tragic suicide, Dr. Jeffrey Lieberman discusses how we can better recognize and treat factors that predispose to suicidality.
  • A New 'Champion of Mental Health Care'   Welcome new legislation has the potential to further mental health research and improve patient care.
  • US Biomedical Funding Slows, Asia's Explodes   American Psychiatric Association president Dr. Jeffrey Lieberman discusses 2 new reports reflecting the bleak state of biomedical research funding in the United States.
  • Explaining the Rise in ADHD   American Psychiatric Association president Dr. Jeffrey Lieberman discusses a recent New York Times article looking at the sky-high rates of ADHD in the United States.
  • So Near, Yet So Far: Achieving Parity in Mental Health Care   APA president Dr. Jeffrey Lieberman on how mental health parity and healthcare reform might affect the field of psychiatry.
  • An Important Look at Mortality in Mental Illness   Is the increased mortality risk among patients with psychiatric illness worsened by psychopharmacologic agents?
  • The 'Darkest Year Ever' for the NIH?   American Psychiatric Association President Dr. Jeffrey Lieberman on how government policies are out of sync with our country's medical needs.
  • How Will Healthcare Reform Affect Psychiatry Coverage?   APA president Dr. Jeffrey Lieberman discusses the need to ensure that mental health parity is incorporated in US healthcare reform.
  • A Mental Health Commitment in Washington   APA President Dr. Jeffrey Lieberman discusses a recent White House event bringing together clinicians, politicians, and celebrities to discuss how US mental healthcare can be improved.
  • Psychiatry Gets More Scientific   DSM-5 has been criticized for being unscientific. But a promising study suggests that useful biomarkers might be around the corner.
  • DSM-5: Setting the Record Straight President-elect of the American Psychiatric Association, Dr. Jeffrey Lieberman, comments on his recent joint statement with the NIMH and the future of psychiatric diagnostics.
  • A Psychiatrist on Hollywood   In the wake of the Academy Awards, Dr. Jeffrey Lieberman reviews 2 recent movies portraying mental illness.
  • A Long Way From 'Insanity and Idiocy'   In late 2012, the DSM-5 was approved by the APA. APA President-elect Dr. Jeffrey Lieberman discusses how far psychiatry has come, where it needs to go, and why it's the right time for a DSM revision.
  • Don't Turn Your Back on Industry, but Keep It Honest   APA President-elect Dr. Jeffrey Lieberman responds to a recent Washington Post article criticizing the pharmaceutical industry's influence on drug research.
  • Runaway Psychotropic Prescribing   Dr. Jeffrey Lieberman addresses the high rate of psychotropic use in the United States. Is it cause for concern?
  • Psychiatric Drug Development: Hope Around the Corner?   Three promising psychiatric drug trials were halted recently, reflecting the gloomy state of drug development in psychiatry. But help might be on the way.
  • When Healthcare Gets a Cold, Psychiatry Gets Pneumonia   Dr. Jeffrey Lieberman discusses the future of psychiatry given that healthcare reform is now a reality.
  • Grief, the DSM-5, and Avoiding Checklist Psychiatry   APA President-Elect Jeffrey Lieberman discusses the ongoing grief vs depression controversy. Plus, a call to place more emphasis on etiology in psychiatric diagnosis.
  • A Major Transformation in Psychiatry?   Dr. Jeffrey Lieberman discusses new and investigational laboratory and imaging tests that have the potential to greatly advance psychiatric diagnosis.
  • Still More Concerns for Psychiatrists?   In the face of continuing mental health care funding cuts, how can psychiatrists call to arms?
  • Cedars-Sinai Nixing Psychiatric Services -- Now What?   In a cost-containment effort, LA's Cedars-Sinai Medical Center will cut most of its psychiatric services this year. Will healthcare reform help prevent further cutbacks across the United States?
  • Practicing 'Rational' Polypharmacy in Psychiatry   Dr. Jeffrey Lieberman discusses a promising adjunct for cognitive impairment in schizophrenia, plus other efforts toward more targeted, efficacious polypharmacy in psychiatry.
  • Mental Health Care: The Times They Are a-Changin'   Medical homes. Accountable care organizations. Dr. Jeffrey Lieberman discusses how psychiatry fits into these and other evolving healthcare models.
  • Psychiatric Diagnosis in the Lab: How Far Off Are We?   Biomarkers, genetic testing, and imaging modalities have shown promise in psychiatric diagnosis. Dr. Jeffrey Lieberman discusses the current and future roles of these approaches in clinical practice.
  • Coping With Disaster: The Mental Health Effects of Trauma   It's been 10 years since the devastating events of 9/11. How were clinicians and patients impacted by the tragedy, and what are the mental health consequences of disasters and traumatic events?
  • Antipsychotics: To Switch or Not to Switch?   Dr. Jeffrey Lieberman discusses the often challenging decision of when and how to switch antipsychotic medications in patients with schizophrenia.
  • Should Clinician Prescribing Data Be Sold?   Dr. Jeffrey Lieberman discusses the ethics of disclosing or selling clinician prescribing data to private entities such as drug manufacturers.
  • APA 2011: What Not to Miss   Dr. Jeffrey Lieberman previews APA 2011 presentations on substance abuse, the DSM, and psychiatry's future, among other sessions not to miss at this year's meeting.
  • Antipsychotics: Injectables vs Orals   How does long-acting injectable risperidone stack up against oral risperidone in terms of safety and efficacy? Dr. Jeffrey Lieberman discusses a recent NEJM article comparing these agents.
  • Antipsychotics: In Search of the Holy Grail   Dr. Jeffrey Lieberman compares the mechanisms of action of existing antipsychotic drugs and postulates where drug development needs to go.
  • How Will a Divided Congress Impact Healthcare Reform?   Dr. Jeffrey Lieberman discusses what effects a GOP majority in the House of Representatives could have on healthcare reform.
  • A Simple Way to Avoid Malpractice Litigation   Dr. Jeffrey Lieberman discusses physician vulnerability to legal accusations and offers a simple means of reducing malpractice risk.
  • Psychiatric Care Shortage: What the Future Holds   Dr. Jeffrey Lieberman discusses the worsening shortage of psychiatric resources and how our population's future mental health needs can be met.
  • Malpractice Watch: Keep an Eye Out for Side Effects   Dr. Jeffrey Lieberman discusses the importance of monitoring and means of addressing side effects associated with antipsychotic therapy.
  • Depression in Pregnancy: It's Not Just the Mothers   Dr. Jeffrey Lieberman discusses the unmet clinical needs and treatment issues associated with peri- and postpartum depression.
  • Metabolic Abnormalities With Antipsychotics: A Management Update   Dr. Jeffrey Lieberman highlights strategies for managing metabolic disturbances and weight gain associated with atypical antipsychotic therapy.
  • Psychiatric Drug Development: Why So Slow?   Dr. Jeffrey A. Lieberman discusses the slow nature of psychotropic drug development, the need for novel treatments, and the recession's impact on therapeutic advances in psychiatry.
  • Antidepressant Efficacy Correlates With Depression Severity   In January, JAMA published a report claiming that certain antidepressants are not effective in mild-to-moderate depression. Should we be surprised? Dr. Jeffrey A. Lieberman discusses the implications of these findings.
  • Omega-3 Fatty Acids in the Prevention of Psychotic Disorders?   Recognizing and managing prodromal psychosis is hampered by nonspecific diagnostic criteria and lack of appropriate therapies. Dr. Jeffrey Lieberman discusses a new study suggesting that long-chain omega-3 fatty acids may prevent progression to a psychotic disorder.
  • Morbidity and Mortality in Schizophrenia: The Mystery of Clozapine   In this video blog, Dr. Lieberman comments on a recent study in the Lancet that investigates the long-term contribution of antipsychotic drugs to mortality in patients with schizophrenia.
  • The Gospel on Antipsychotic Drugs According to CATIE   Dr. Lieberman discusses the efficacy of antipsychotic drugs in patients with schizophrenia in his latest video blog.
  • Treating Schizophrenia and Related Psychotic Disorders   In the first part of a new video blog series, Dr. Jeffrey Lieberman discusses the treatment of schizophrenia and related psychotic disorders.